[Form 4] ADMA Biologics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Form 4 overview: ADMA Biologics (ticker ADMA) disclosed that Chief Financial Officer & Treasurer Brad L. Tade had 9,838 common shares withheld on 06/26/2025 (transaction code “F”). The “F” code means the shares were automatically surrendered to the company to satisfy statutory tax-withholding obligations triggered by the vesting of previously granted restricted stock units (RSUs); it was not an open-market sale.

Post-transaction holdings: Tade’s stated beneficial ownership is 246,542 shares after the withholding event. This figure comprises:

• 186,127 unvested RSUs spread across four grant dates (June 2023, Feb 2024, July 2024, Feb 2025) that vest quarterly over four years, contingent on continued employment.
• 24,415 fully vested shares accumulated through open-market purchases and past RSU settlements.
• The remaining balance represents fully vested shares already held.

No derivative activity was reported in Table II, and there were no purchases or sales of stock options or other instruments.

Investor takeaway: The filing is routine and signals mandatory tax withholding rather than discretionary selling. Insider equity alignment remains intact; the CFO continues to hold a meaningful stake that will grow as RSUs vest.

Insights

Senior Financial Analyst

TL;DR: Routine tax-withholding; no bearish signal.

The 9,838-share “F” transaction merely covers payroll taxes on RSU vesting, leaving Tade with 246k shares (incl. 186k unvested RSUs). No open-market disposal occurred, so liquidity or sentiment impact is negligible. Insider equity still aligns management with shareholders, supporting governance best practices.

Corporate Governance Specialist

TL;DR: Neutral governance event; incentive structure intact.

The staggered four-year RSU schedule incentivizes long-term performance. Automatic share withholding for taxes is standard and does not reflect strategy or outlook. Continued sizable ownership (≈246k shares) indicates ongoing commitment but does not materially change voting power or control metrics.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tade Brad L.

(Last) (First) (Middle)

C/O ADMA BIOLOGICS, INC.

5800 PARK OF COMMERCE BLVD. NW

(Street)

BOCA RATON FL 33487

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ADMA BIOLOGICS, INC. [ ADMA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CFO and Treasurer

3. Date of Earliest Transaction (Month/Day/Year)
06/26/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/26/2025		F		9,838(1)	D	$18.4	246,542(2)(3)(4)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units ("RSUs"). This is not an open market sale of securities.

2. Includes, as of the transaction date, (i) 62,227 unvested RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 72,400 unvested RSUs granted on July 24, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;

3. (continued from footnote 2) (iii) 37,500 unvested RSUs granted by the Company on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;

4. (continued from footnote 3) (iv) 50,000 unvested RSUs, granted by the Company on June 26, 2023, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; and (v) 24,415 shares acquired in open market purchases and pursuant to the vesting of RSUs after the withholding of shares to cover applicable taxes.

	/s/ Brad L. Tade, by Adam S. Grossman as Attorney-in-fact	06/30/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many ADMA shares did CFO Brad Tade surrender on 06/26/2025?

9,838 shares were automatically withheld to satisfy tax obligations upon RSU vesting.

Was the 9,838-share transaction an open-market sale?

No. The Form 4 shows code “F”, indicating shares were withheld by the issuer for taxes, not sold on the market.

What is Brad Tade’s total beneficial ownership after the transaction?

The filing lists 246,542 ADMA shares beneficially owned, including unvested RSUs.

How many RSUs held by the CFO are still unvested?

Approximately 186,127 RSUs remain unvested across four grant dates.

Did the Form 4 report any trades in derivative securities like options or warrants?

No. Table II showed no derivative security transactions during the period.